Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts.

Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts.

Disease-modifying antirheumatic drugs are used in virtually all patients with established rheumatoid arthritis. An increasingly large number of new drugs is now available. Furthermore, old therapies are being used in novel ways. Treatment is now begun earlier and patients are rarely left untreated....

書誌詳細
主要な著者:	Emery, P, Luqmani, R, Gordon, C
フォーマット:	Journal article
言語:	English
出版事項:	1994

類似資料

Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
著者:: Abhishek Zanwar, 等
出版事項: (2017-01-01)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
著者:: Xia Y, 等
出版事項: (2016-05-01)

The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
著者:: Edwards, C, 等
出版事項: (2007)

The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
著者:: Gregory Fleury, 等
出版事項: (2017-12-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
著者:: Yu. V. Muraviev, 等
出版事項: (2018-12-01)

Lung lesion caused by the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
著者:: Yuriy Vladimirovich Murav'ev, 等
出版事項: (2010-12-01)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
著者:: Smolen, J, 等
出版事項: (2017)

Dynamics of T- and B-lymphocytes in patients with rheumatoid arthritis, receiving biological disease-modifying antirheumatic drugs
著者:: A. V. Martynova, 等
出版事項: (2022-02-01)

Disease-Modifying Antirheumatic Diets: The New Treatment Modalities for Rheumatoid Arthritis
著者:: Shweta Khanna, 等
出版事項: (2018-07-01)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
著者:: Soo-Kyung Cho, 等
出版事項: (2023-07-01)

Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
著者:: A. O. Bobkova, 等
出版事項: (2023-07-01)

Real‐World Treatment Effectiveness of Disease‐Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
著者:: Yinzhu Jin, 等
出版事項: (2023-11-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
著者:: Yinzhu Jin, 等
出版事項: (2017-07-01)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
著者:: Emma Sullivan, 等
出版事項: (2020-04-01)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
著者:: Judge, AD, 等
出版事項: (2017)

Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis
著者:: Bong-Woo Lee, 等
出版事項: (2024-09-01)

Comparison of the Effect of Disease: Modifying Antirheumatic Drugs Alone or in Combination with Biologic Drugs in the Outcome of Patients with Rheumatoid Arthritis
著者:: Maryam Mousavi, 等
出版事項: (2019-01-01)

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.
著者:: Griffiths, R, 等
出版事項: (2001)

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
著者:: Griffiths, R, 等
出版事項: (2000)

Predictors of radiological progression of rheumatoid arthritis while receiving conventional synthetic disease-modifying antirheumatic drugs
著者:: O. B. Iaremenko, 等
出版事項: (2024-12-01)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
著者:: Giovanni Adami, 等
出版事項: (2023-01-01)

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
著者:: van Heuckelum M, 等
出版事項: (2019-07-01)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
著者:: Ko-Jen Li, 等
出版事項: (2021-07-01)

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
著者:: Stefan Winkler, 等
出版事項: (2021-11-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
著者:: Yu. V. Muravyev, 等
出版事項: (2018-09-01)

Initiation of Disease‐Modifying Antirheumatic Drugs in Older Medicare Beneficiaries With New Diagnosis of Late‐Onset Rheumatoid Arthritis
著者:: Jiha Lee, 等
出版事項: (2023-12-01)

Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease‐Modifying Antirheumatic Drugs
著者:: Gulsen Ozen, 等
出版事項: (2019-09-01)

Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial
著者:: Jon T. Giles, 等
出版事項: (2021-06-01)

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
著者:: Yinan Huang, 等
出版事項: (2023-09-01)

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
著者:: Kemper Alex R, 等
出版事項: (2012-03-01)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
著者:: Susan Siyu Wang, 等
出版事項: (2023-07-01)

Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain
著者:: Blanca Hernández Cruz, 等
出版事項: (2020-10-01)

EFFECTS OF SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS, BIOLOGICAL AGENTS, AND PSYCHOPHARMACOTHERAPY ON THE MENTAL DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
著者:: A. A. Abramkin, 等
出版事項: (2017-09-01)

Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
著者:: A. E. Karateev, 等
出版事項: (2022-09-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
著者:: E. N. Koltsova, 等
出版事項: (2022-12-01)

Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy
著者:: Irma Convertino, 等
出版事項: (2023-09-01)

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database
著者:: Wan Xiong, 等
出版事項: (2024-11-01)

Predictors at diagnosis for start of biologic disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis: a cohort study
著者:: Carl Turesson, 等
出版事項: (2024-02-01)

In vitro effect of biological and conventional disease-modifying antirheumatic drugs on fibrocyte differentiation in patients with rheumatoid arthritis and healthy controls
著者:: Helene Broch Tenstad, 等
出版事項: (2021-10-01)

Use of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Supporting Shared Decision‐Making Between Patients With Cancer and Clinicians
著者:: Namrata Singh, 等
出版事項: (2023-06-01)